This randomised controlled trial ( DATA-Switch ) is a preplanned extension of the denosumab and teriparatide administration study ( DATA ) , in which 94 postmenopausal osteoporotic women were randomly assigned to receive 24 months of teriparatide ( 20 mg daily ) , denosumab ( 60 mg every 6 months ) , or both drugs .